Deep within the aphotic zones of the Amazon’s ferruginous caves, a hidden world of microbial “dark matter” holds immense potential as a source for pharmacological innovation. A pioneering metabolomic survey of these extreme environments isolates rare bacterial genera that thrive in these iron-rich landscapes. They use SIRIUS to identify and classify chemical features, including potent cyclopeptides demonstrating growth inhibition against cancer cell lines.

Read the full blog post.

N. N. Kato et al. Chem. Biodivers. (2026) doi: 10.1002/cbdv.202502912

Offshore produced water discharges introduce over 240 billion liters of complex chemical mixtures into the marine environment annually. In a case study using produced water from North Sea offshore oil platforms, researchers demonstrated that traditional monitoring significantly underestimates the persistence of discharged chemicals. They introduce a novel analytical framework using advanced non-target analysis and computational workflows, including SIRIUS to highlight a significant “hidden burden” of persistent pollutants.

Read the full blog post.

M. T. Møller et al. Environ. Sci. Technol. (2025) doi: 10.1021/acs.est.5c08802

The maturation of the gut microbiome during the first six months of life is a foundational process, playing a key role in metabolic programming and training of the immune system, but these patterns remain critically underexplored in populations from low- and middle-income countries. To address this gap, an observational, longitudinal study profiled the developing gut microbiome and metabolome in Bangladesh using a multi-omics approach. Systematic classification and metabolite annotation was achieved using SIRIUS. The overall aim was to understand how maternal and environmental factors—specifically delivery mode, maternal milk composition, and household water treatment—shape this foundational postnatal development.

Read the full blog post.

K. E. Kvitne et al. Cell Host Microbe (2025) doi: 10.1016/j.chom.2025.11.002

In pharmacology, one of the most significant challenges is the variability in how patients respond to the same drug. While factors like genetics and lifestyle are known to play a role, emerging research points to a hidden player: the human gut microbiota. This vast community of trillions of microbes is an active participant in our health, influencing everything from nutrient absorption to the efficacy of our medications. Using advanced computational tools like SIRIUS to analyze mass spectrometry data, researchers investigated how gut microbiota alter the chemical structure of GPCR drugs.

Read the full blog post.

Q. Wu et al. Nat. Chem. (2025) doi: 10.1038/s41557-025-01789-w